# Quitting cigarettes, vaping and nicotine pouches

Reviewed 2026-11-10

Source edition: [14.8% vape. 3.4% smoke.](https://www.andreheeg.com/archive/14-8-vape-3-4-smoke) (2026-11-01).

Quit rates in randomized trials, continued nicotine use and the limits of the FDA’s claim for ZYN.

## Key takeaways

- A UK trial with behavioral support found that 18.0% of people assigned an e-cigarette had stopped smoking at one year. The figure was 9.9% among those assigned nicotine replacement. [[9]](<https://doi.org/10.1056/NEJMoa1808779>)
- Quitting smoking was associated with longer survival at every age in four national cohorts. Benefits were apparent within three years. [[3]](<https://doi.org/10.1056/EVIDoa2300272>)

## Questions

### Is vaping the most effective option for every smoker?

The direct evidence favors nicotine e-cigarettes over nicotine replacement in the trials reviewed. Varenicline and cytisine also ranked among the most effective options in a broader comparison. The research does not establish a single winner. [[8]](<https://doi.org/10.1002/14651858.CD010216.pub11>) [[16]](<https://www.cochrane.org/evidence/CD015226_how-effective-are-medications-and-e-cigarettes-quitting-smoking-and-what-works-best>)

### How many people who quit were still vaping a year later?

In the UK trial, 80% of successful quitters assigned an e-cigarette were still using it at one year. The corresponding figure for nicotine replacement was 9%. [[9]](<https://doi.org/10.1056/NEJMoa1808779>)

### What if someone keeps smoking as well as vaping?

A US study measured toxicants in urine. People using both products had high exposure, and cigarette frequency mattered. The measurements describe exposure at the time of sampling rather than future disease rates. [[10]](<https://doi.org/10.1001/jamanetworkopen.2018.5937>)

### What exactly did the FDA authorize for ZYN?

The June 2026 order lets 20 specific products carry a lower-risk claim for adults who fully replace cigarettes. The comparison was with continued smoking. The authorization covers neither starting nicotine for focus nor every pouch on the market. [[14]](<https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-20-zyn-nicotine-pouches-be-marketed-specific-modified-risk-claim>)

### How common was vaping among US school students?

In the 2025 National Youth Tobacco Survey, 5.2% of middle and high school students reported e-cigarette use within the preceding 30 days. Among current users, 41.2% reported frequent use. [[6]](<https://doi.org/10.1093/ntr/ntag116>)

### Can a pouch’s strength be inferred from its packaging?

Researchers measured nicotine in 44 European products and found a wide range of doses. Labels often lacked a clear indication of nicotine content. [[13]](<https://doi.org/10.1136/tc-2022-057280>)

## References

1. [Gioino, C. (2026). Palantir and other tech companies are stocking offices with nicotine products to increase worker productivity. Fortune.](<https://fortune.com/2026/03/04/palantir-tech-companies-offices-vending-machines-tobacco-worker-productivity/>)
2. [Hashibe, M., Brennan, P., Chuang, S.-C., Boccia, S., Castellsague, X., Chen, C., Curado, M. P., Dal Maso, L., Daudt, A. W., Fabianova, E., Fernandez, L., Wünsch-Filho, V., Franceschi, S., Hayes, R. B., Herrero, R., Kelsey, K., Koifman, S., La Vecchia, C., Lazarus, P., . . . Boffetta, P. (2009). Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiology, Biomarkers & Prevention, 18(2), 541–550.](<https://doi.org/10.1158/1055-9965.EPI-08-0347>)
3. [Cho, E. R., Brill, I. K., Gram, I. T., Brown, P. E., & Jha, P. (2024). Smoking cessation and short- and longer-term mortality. NEJM Evidence, 3(3), EVIDoa2300272.](<https://doi.org/10.1056/EVIDoa2300272>)
4. [Marron, M., Boffetta, P., Zhang, Z.-F., Zaridze, D., Wünsch-Filho, V., Winn, D. M., Wei, Q., Talamini, R., Szeszenia-Dabrowska, N., Sturgis, E. M., Smith, E., Schwartz, S. M., Rudnai, P., Purdue, M. P., Olshan, A. F., Eluf-Neto, J., Muscat, J., Morgenstern, H., Menezes, A., . . . Hashibe, M. (2010). Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. International Journal of Epidemiology, 39(1), 182–196.](<https://doi.org/10.1093/ije/dyp291>)
5. [Agaku, I. (2026). Tobacco product use among U.S. adults, 2023–2024. NEJM Evidence.](<https://doi.org/10.1056/EVIDpha2500339>)
6. [Park-Lee, E., Dutra, L. M., Cowan, H., Levine, B., Sawdey, M. D., Cooper, M., Merson, B., Valverde, R., Bradfield, B., Lennon, J., Freedman, N. D., Ambrose, B. K., & Cullen, K. A. (2026). Tobacco product use among middle and high school students in the United States: National Youth Tobacco Survey, 2025. Nicotine & Tobacco Research. Advance online publication.](<https://doi.org/10.1093/ntr/ntag116>)
7. [U.S. Department of Health and Human Services. (2016). E-cigarette use among youth and young adults: A report of the Surgeon General. Office of the Surgeon General.](<https://www.ncbi.nlm.nih.gov/books/NBK538680/>)
8. [Lindson, N., Livingstone-Banks, J., Butler, A. R., McRobbie, H., Bullen, C. R., Hajek, P., Wu, A. D., Begh, R., Theodoulou, A., Ma, C., Notley, C., Rigotti, N. A., Turner, T., Fanshawe, T., & Hartmann-Boyce, J. (2026). Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews, 8, CD010216.](<https://doi.org/10.1002/14651858.CD010216.pub11>)
9. [Hajek, P., Phillips-Waller, A., Przulj, D., Pesola, F., Myers Smith, K., Bisal, N., Li, J., Parrott, S., Sasieni, P., Dawkins, L., Ross, L., Goniewicz, M., Wu, Q., & McRobbie, H. J. (2019). A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine, 380(7), 629–637.](<https://doi.org/10.1056/NEJMoa1808779>)
10. [Goniewicz, M. L., Smith, D. M., Edwards, K. C., Blount, B. C., Caldwell, K. L., Feng, J., Wang, L., Christensen, C., Ambrose, B., Borek, N., van Bemmel, D., Konkel, K., Erives, G., Stanton, C. A., Lambert, E., Kimmel, H. L., Hatsukami, D., Hecht, S. S., Niaura, R. S., . . . Hyland, A. J. (2018). Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Network Open, 1(8), e185937.](<https://doi.org/10.1001/jamanetworkopen.2018.5937>)
11. [Tattan-Birch, H., Hartmann-Boyce, J., Kock, L., Simonavicius, E., Brose, L., Jackson, S., Shahab, L., & Brown, J. (2022). Heated tobacco products for smoking cessation and reducing smoking prevalence. Cochrane Database of Systematic Reviews, 1, CD013790.](<https://doi.org/10.1002/14651858.CD013790.pub2>)
12. [Heishman, S. J., Kleykamp, B. A., & Singleton, E. G. (2010). Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology, 210(4), 453–469.](<https://doi.org/10.1007/s00213-010-1848-1>)
13. [Mallock, N., Schulz, T., Malke, S., Dreiack, N., Laux, P., & Luch, A. (2024). Levels of nicotine and tobacco-specific nitrosamines in oral nicotine pouches. Tobacco Control, 33(2), 193–199.](<https://doi.org/10.1136/tc-2022-057280>)
14. [U.S. Food and Drug Administration. (2026). FDA authorizes 20 ZYN nicotine pouches to be marketed with specific modified risk claim.](<https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-20-zyn-nicotine-pouches-be-marketed-specific-modified-risk-claim>)
15. [National Health Service. (n.d.). Mouth cancer: Symptoms.](<https://www.nhs.uk/conditions/mouth-cancer/symptoms/>)
16. [Lindson et al. (2023). Pharmacological and electronic cigarette interventions for smoking cessation in adults.](<https://www.cochrane.org/evidence/CD015226_how-effective-are-medications-and-e-cigarettes-quitting-smoking-and-what-works-best>)

This pack covers the companion statements above. It is educational and does not provide individual medical advice or certify every claim in the original newsletter.
